O ur genomes face many threats, both from DNA damage and from aberrancies during cell division 1 . Failure to protect the genome can cause alterations and ultimately result in oncogenic transformation 2 . DSBs are a particularly perilous type of DNA damage and can be repaired by HDR or NHEJ 3 . NHEJ is a simpler pathway that religates the ends; however, inappropriate use of NHEJ can result in harmful deletions and translocations 4,5 , whereas HDR ensures fidelity by using the sister chromatid as a template.
REV7, along with the spindle assembly checkpoint (SAC) protein MAD2, the meiotic regulators HORMAD1/2 and the autophagy protein complex ATG13-ATG101, are members of the HORMA family 29 . Although HORMA proteins perform widely disparate cellular functions, their tertiary structure is extremely similar. A key feature is their C-terminal seatbelt domain, which latches over partners. MAD2 and Hop1 (the yeast homologue of HORMAD1/2) exist in two conformational states in which the seatbelt is either open in an unliganded state or closed over a partner 30, 31 .
In the case of MAD2, conformational switching is essential for its function. Only the closed form of MAD2 (C-MAD2) is active and capable of CDC20 binding and SAC activation 30, 32 . The conformational dynamics of MAD2 and, therefore, its activity are tightly regulated by two opposing proteins-MAD1, which promotes the closing of MAD2 over CDC20 to activate the SAC, and the AAA+ ATPase TRIP13, which opens MAD2, therefore turning off the SAC 33, 34 .
Intriguingly, published structures of REV7 with either REV3 or CAMP revealed a conformation that resembles C-MAD2 (refs. 24, 35, 36 ). However, an inactive open form of REV7 and the factors that regulate its conformation are unknown. Here we demonstrate that REV7 can stably adopt distinct open and closed conformations, and that only the closed conformation is proficient at forming the Shieldin and Pol-ζ complexes. Furthermore, we identified that TRIP13 is a modulator of REV7 conformation, making TRIP13 a key regulator of pathway choice at both DSBs and replication blockages. Importantly, we found that overexpression of TRIP13, a common feature in cancer, causes PARPi resistance through the disruption of the REV7-SHLD3 interaction, and correlates with poor survival of patients.
Results

REV7-Shieldin physically interacts with TRIP13.
To identify REV7 regulators, we purified tandem-affinity-tagged REV7 complexes and analysed them using mass spectrometry ( Fig. 1a,b ). Interestingly, a top hit was the AAA+ ATPase TRIP13, a negative regulator of the HORMA proteins MAD2 and HORMAD1/2 (Extended Data Fig. 1a ). We confirmed the interaction using reciprocal immunoprecipitation (IP) of TRIP13, which pulled down endogenous REV7 (Fig. 1c ). We also found that SHLD1-3 are able to co-IP TRIP13, indicating that TRIP13 interfaces with the REV7-Shieldin complex (Extended Data Fig. 1b ). The interaction between TRIP13 and SHLD3 was particularly strong, consistent with the direct REV7-SHLD3 interaction 11 . Interestingly, the interaction between REV7 and TRIP13 was not affected by X-ray or ultraviolet (UV) radiation nor treatment with olaparib and mitomycin C (MMC; Fig. 1c , Extended Data Fig. 1c,d) , similar to the damageindependent interaction between REV7 and Shieldin 11 .
TRIP13 promotes PARPi resistance through REV7-Shieldin. To test whether TRIP13 negatively regulates REV7 in the context of Shieldin, we generated TRIP13 −/− U2OS cell lines (Extended Data Fig. 1e ). We observed that TRIP13 −/− cells had increased sensitivity to olaparib, but could be rescued by TRIP13 cDNA expression, in contrast to the resistance of REV7 −/− cells 26 (Fig. 1d,e ) and consistent with an antagonistic role. As the PARPi resistance associated with Shieldin inactivation is clinically relevant, we investigated whether this could be achieved by TRIP13 overexpression. Indeed, U2OS cells stably overexpressing TRIP13, but not cells stably overexpressing the ATPase-dead TRIP13 E253Q mutant, exhibited a modest induction of PARPi resistance (Extended Data Fig. 1f,g) . Importantly, knockdown of the canonical TRIP13 substrate, MAD2, had no effect on olaparib resistance or HDR as measured using a direct repeat green fluorescence protein (DR-GFP) assay 37 (Extended Data Fig. 1h-j) .
To definitively place TRIP13 in the REV7 pathway for PARPi resistance, we queried epistasis by overexpressing TRIP13 in REV7 −/− cells. Although TRIP13 overexpression in REV7 wild-type cells conferred olaparib resistance, it had no effect in REV7 −/− cells ( Fig. 1f) , consistent with our model. Moreover, knocking out REV7 in TRIP13 −/− cells suppressed their sensitivity to olaparib (Extended Data Fig. 1k,l) . Finally, we overexpressed TRIP13 in the SHLD2deficient HCC1937 breast cancer cell line 14 . Consistent with the REV7 −/− case, TRIP13 overexpression had no effect in HCC1937 cells ( Fig. 1g , Extended Data Fig. 1m ), indicating that TRIP13 promotes olaparib resistance through the regulation of REV7-Shieldin.
Purified REV7 adopts two conformations in solution. TRIP13 regulates MAD2 by catalysing its transition from a closed (C-MAD2) to an open (O-MAD2) conformation, thereby releasing its binding partner CDC20 (refs. 30, 33 ). Previously published crystal structures of REV7 bound to REV3 and CAMP revealed a conformation that is analogous to C-MAD2 (refs. 24, 35, 36 ; Fig. 2a ); however, a REV7 form that corresponds to O-MAD2 has not been observed to date.
To determine whether REV7 also exists in two conformations, we purified REV7 from Escherichia coli. We utilized the well-characterized REV7 R124A mutant that cannot form dimers but maintains interactions with binding partners 38 -an approach used previously 30 with MAD2. As expected, purified REV7 R124A was predominantly monomeric (Extended Data Fig. 2a ). O-MAD2 and C-MAD2 can be separated using anion exchange chromatography (AEC) 30 , so we investigated whether distinct REV7 conformers could be similarly detected. Indeed, when we performed AEC on REV7 R124A , we observed two discrete populations, one that eluted at around 100 mM NaCl (REV7-F1) and the other at approximately 350 mM NaCl (REV7-F2; Fig. 2b ). We confirmed that these two fractions were both REV7 using western blot (Extended Data Fig. 2b ).
To study the dynamics of the REV7 pools, we isolated REV7-F1 and REV7-F2 and ran them through the AEC protocol again. We observed very little conversion of F1 to F2 and absolutely no conversion of F2 to F1 (Extended Data Fig. 2b ), implying that the populations were mostly stable. Given the low level of F1-to-F2 conversion, we investigated whether the conversion would proceed to completion over time. Indeed, left overnight at 37 °C, REV7-F1 converted entirely to F2 (Extended Data Fig. 2b ).
As a complementary approach to query REV7 conformation, we purified 15 N-labelled REV7 and assayed each pool using heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) spectroscopy. Consistent with our model, the NMR spectra of the two populations were remarkably different ( Fig. 2c) , indicating large-scale structural changes. Interestingly, the REV7-F1 spectrum is similar to that of partner-bound REV7 38 , suggesting correspondence with C-REV7.
REV7 adopts an active closed form and an inactive open form.
To determine whether the peaks correspond to open and closed REV7, we purified a REV7 R124A Δseatbelt mutant that lacks the C-terminal 10 amino acids, and is homologous to a MAD2 mutant that cannot adopt the closed conformation. Consistent with our prediction that this mutant can exist in only one conformation, we observed only a single population that eluted at the same salt concentration as REV7-F2 ( Fig. 2d ). This indicates that REV7-F2 is probably O-REV7, whereas REV7-F1 corresponds to C-REV7, consistent with the NMR data ( Fig. 2c ).
It is puzzling that the ATPase TRIP13 should be required to convert C-REV7 to O-REV7, given that C-REV7 can spontaneously convert to O-REV7 at a physiological temperature (Extended Data Fig. 2b ). However, the true substrate for TRIP13 is C-REV7 in complex with a seatbelt binder ( Fig. 2e ). To test whether C-REV7 is stabilized after partner binding, we utilized a known REV7 seatbeltbinding motif (SBM) peptide derived from its Pol-ζ-binding partner, REV3. Notably, pre-incubation of REV7 with the SBM peptide stabilized C-REV7, preventing any conversion, even after overnight incubation (Fig. 2f ), and providing a probable explanation for the ATPase requirement.
Closed REV7 specifically interacts with SHLD3 through a seatbelt-binding mechanism. Crystal structures of REV7 in complex with REV3 and CAMP revealed a common binding mechanism, whereby the REV7 seatbelt domain binds to a short conserved SBM: (R/K)PxxxxP(T/S) 35, 36 (Extended Data Fig. 2c,d ). Interestingly, SHLD3 also harbours an SBM in its REV7-interacting region 11 (Extended Data Fig. 2d ), suggesting that SHLD3 is also a seatbelt interactor. To test this, we purified GST-tagged SHLD3 from E. coli and incubated it with either REV7 R124A or REV7 R124A Δseatbelt . As expected, GST-SHLD3 pulled down full-length REV7, but not the Δseatbelt mutant (Extended Data Fig. 2e ), implying that REV7 and SHLD3 bind through a seatbelt-SBM interaction. Furthermore, when we incubated GST-SHLD3 with isolated REV7 fractions, we observed that only C-REV7 was able to bind ( Fig. 2g ). Together, these data indicate a regulatory mechanism in DNA repair whereby REV7 is controlled by conformational alteration.
TRIP13 can dissociate C-REV7-SHLD3 complexes in vitro. As TRIP13 inactivates MAD2 by releasing the seatbelt interactor of MAD2, CDC20, we tested whether purified TRIP13 could similarly disassemble C-REV7-SHLD3 in vitro. Purified TRIP13 exhibited robust ATPase activity (Extended Data Fig. 3a ,b) and dissociated in vitro assembled REV7-SHLD3 complexes in an ATP-dependent manner, as evidenced by the release of REV7 from immobilized GST-SHLD3 complexes ( Fig. 3a-c) . Thus, TRIP13 ATPase activity can disrupt the REV7-Shieldin complex in vitro by disengaging the seatbelt interactor SHLD3 from REV7.
TRIP13 antagonizes REV7 function in cells.
To determine whether TRIP13 similarly affected REV7 dynamics in cells, we performed IPs with GFP-tagged SHLD3 in wild-type, TRIP13 −/− and TRIP13-overexpressing cells. Consistent with our in vitro findings, TRIP13 −/− cells showed increased REV7-SHLD3 interaction, whereas TRIP13 overexpression decreased the interaction Table of high-confidence REV7-interacting proteins and the average abundance of proteins recovered from three biologically independent experiments. c, Western blot of Flag IP from HEK293T cells transfected with empty vector or Flag-TRIP13 with or without DNA damage. d, A 14-d clonogenic survival assay of wild-type, REV7 −/− and TRIP13 −/− USOS cell lines treated with various doses of olaparib; n = 3 independent experiments. Wild type versus TRIP13 −/− 3, *P = 0.0001; wild type versus TRIP13 −/− 7, *P = 0.002; statistical analysis was performed using two-way analysis of variance (ANOVA). e, A 14-d clonogenic survival assay of wild-type or TRIP13 −/− U2OS cells with or without expression of TRIP13 cDNA after treatment with olaparib; n = 3 biologically independent experiments. Wild type versus TRIP13 −/− + empty vector, *P = 0.002; TRIP13 −/− + empty vector versus TRIP13 −/− + TRIP13, *P = 0.002; statistical analysis was performed using two-way ANOVA. f, A 14-d clonogenic survival assay of wild-type and REV7 −/− U2OS cells with or without TRIP13 overexpression treated with various doses of olaparib; n = 3 biologically independent experiments. Wild type + empty vector versus wild type + TRIP13, *P = 0.005; REV7 −/− + empty vector versus REV7 −/− + TRIP13, P = 0.31; statistical analysis was performed using two-way ANOVA. g, A 5-d cytotoxicity analysis of SHLD2-deficient HCC1937 cells infected with pBabe-empty vector or pBabe-TRIP13 treated with the indicated doses of olaparib; n = 5 biologically independent experiments. P = 0.58; statistical analysis was performed using two-way ANOVA. For d-g, data are mean ± s.e.m. Immunoblots are representative of at least two independent experiments. Source data are available online.
( Fig. 3d,e ). Furthermore, we observed the same effect in multiple cell lines and with Flag-tagged SHLD3 (Extended Data Fig. 3c ). Importantly, the REV7-SHLD1 association was unaltered in TRIP13 −/− cells (Extended Data Fig. 3d ,e), consistent with reports that SHLD1 binds to REV7 through a distinct interface from SHLD3 ( Fig. 3f ) 10 . We next investigated whether the status of TRIP13 alters the recruitment of REV7 to DNA damage by SHLD3 ( Fig. 3f ). Indeed, TRIP13 −/− cells exhibited an increase in REV7 focus formation after induction of DSB by ionizing radiation (IR; Fig. 3g ,h). Conversely, overexpression of TRIP13 reduced REV7 focus formation (Extended Data Fig. 3f,g) . We observed the same effect on REV7 recruitment when we queried its chromatin association after IR (Extended Data Fig. 3h ). Importantly, focus formation of 53BP1 and RIF1 was unaffected by TRIP13 status (Extended Data Fig. 3i ,j), indicating that DSB repair kinetics and upstream components are unaltered. It is not possible to directly assess the conformational status of REV7 in cells using AEC, as REV7 binding partners would affect the elution profile. However, as C-REV7 can form seatbelt-dependent complexes, whereas O-REV7 cannot ( Fig. 2g ), we expected that C-REV7 will more often exist as a part of large complexes, whereas O-REV7 will not. To assay this, we performed size-exclusion chromatography (SEC) on cell lysates from wild-type and TRIP13 −/− cells. Consistent with our expectations, we observed a higher proportion of low-molecular-mass REV7 in wild-type cells compared with the proportion in TRIP13 −/− cells (Fig. 3i ). Together, these results indicate that TRIP13 is a negative regulator of REV7 seatbelt association and, therefore, activity in cells.
TRIP13 promotes resection and homologous recombination.
As TRIP13 negatively regulates REV7, an anti-resection factor, we expected that TRIP13 enhances end resection and promotes HDR. We first assayed resection using the single-molecule analysis of resection tracts (SMART) method 39 . In TRIP13 −/− cells, we observed a significant decrease in resection tract lengths ( Fig. 4a,b ), consistent with REV7-Shieldin hyperactivation. By contrast, REV7 −/− cells showed longer resection tracts ( Fig. 4a,b ). TRIP13 overexpression conferred a similar increase in resection (Extended Data Fig. 4a ,b), probably through REV7-Shieldin inactivation.
As a complementary approach, we monitored phosphorylation of the single-stranded DNA (ssDNA) binding protein RPA on S33, which marks resected DNA 40 . Consistent with our SMART results, TRIP13 −/− cells had decreased numbers of phosphorylated RPA (pRPA) foci after IR treatment compared with the control; by contrast, REV7 −/− and TRIP13-overexpressing cells showed an increase in pRPA foci ( Fig. 4c,d , Extended Data Fig. 4c ). Similar results were observed in HeLa cells and western blot analysis (Extended Data Fig. 4d-f ). Importantly, the decrease in pRPA foci in TRIP13 −/− cells was not rescued by expression of the ATPase-dead form of TRIP13 (Extended Data Fig. 4f ).
After end resection, RPA is replaced by the recombinase RAD51 for HDR to proceed 3 . TRIP13 −/− cells were compromised for RAD51 focus formation, whereas TRIP13-overexpressing cells showed an increase ( Fig. 4e ,f, Extended Data Fig. 4g ), consistent with the posited REV7-antagonistic function of TRIP13. We recapitulated these results in HeLa cells (Extended Data Fig. 4h ). Notably, a role for TRIP13 in RAD51 loading during meiotic recombination has been reported previously, although the mechanism remained unclear 41 . Our findings shed light on this interesting result; however, further studies on REV7-Shieldin in meiotic recombination are required.
To assay the effect of TRIP13 on HDR completion, we utilized a DR-GFP reporter cassette assay 37 . As expected, we observed a modest decrease in HDR after TRIP13 knockdown, and an increase in HDR after TRIP13 overexpression ( Fig. 4g , Extended Data Fig. 4i ,j). Taken together, these data demonstrate that TRIP13 promotes HDR through inactivation of REV7-Shieldin.
TRIP13 also modulates REV7 function in TLS. REV7-mediated TLS is essential for ICL repair, and homozygous mutation of REV7 causes Fanconi anaemia, which is a genetic disease that is characterized by ICL repair deficiency 26 . We found that overexpression of TRIP13 resulted in cellular sensitivity to MMC and increased formation of chromosome aberrations and radials ( Fig. 5a -c)-which are hallmarks of defective ICL repair-indicating that TRIP13 also affects REV7 function in ICL repair. TRIP13 overexpression similarly sensitized cells to UV-induced base damage ( Fig. 5d ). Furthermore, knockdown of TRIP13 increased UV-induced mutagenesis, as measured using a supF assay ( Fig. 5e , Extended Data Fig. 5a ), further supporting the notion that TRIP13 negatively regulates REV7 in the Pol-ζ context.
Interestingly, TRIP13 −/− cells were not resistant to UV radiation and ICL-inducing agents (Extended Data Fig. 5b ,c), suggesting that hyperactive TLS serves only to increase mutation frequency without conferring a survival advantage. Similarly, knockdown of TRIP13 did not affect radial chromosome prevalence (Extended Data Fig. 5d ). It did, however, result in severe cohesinopathy (Extended Data Fig.  5d ), probably due to dysfunction of the SAC 34 through MAD2.
We suspected that TRIP13 regulates TLS by antagonizing the seatbelt-dependent REV7-REV3 interaction. To test this, we expressed a GFP-tagged fragment of REV3 containing the REV7-binding SBM and performed IP. As expected, TRIP13 −/− cells showed greater REV7-REV3 association, whereas TRIP13-overexpressing cells exhibited a decrease in REV7-REV3 association ( Fig. 5f,g) . These results imply that TRIP13 operates in a similar manner, regardless of whether it is engaged with Pol-ζ or Shieldin, thereby regulating two distinct DNA repair pathways.
TRIP13 is often overexpressed in breast cancer and correlates with BRCA1 deficiency. The function of REV7-Shieldin in DSB repair is clinically important because it affects the sensitivity of cancer cells to PARPi 42 . As TRIP13 overexpression enhances HDR and PARPi resistance, even in HDR-proficient cells (Fig. 4) , and is frequently observed in many types of cancer (Extended Data Fig. 6a ,b), we wondered whether TRIP13 overexpression is a clinically important factor in HDR-deficient cancer cells.
We first analysed breast cancer data from the Cancer Genome Atlas (TCGA). Importantly, although the HDR defect of BRCA1deficient cells can be rescued by Shieldin loss, the same is not true for BRCA2-deficient cancers, as BRCA2 acts downstream of resection 8 . Consistent with this, BRCA1-mutant breast cancer cells showed a significant increase in TRIP13 expression compared with BRCA-proficient cells, whereas BRCA2-deficient cells did not ( Fig. 6a ). This suggests that TRIP13 upregulation may be clinically important in BRCA1-deficient cancers.
BRCA1 mutations are relatively rare in breast cancer; however, functional HDR deficiency is more prevalent. To correlate TRIP13 expression with functional HDR deficiency in breast cancer, we queried the prevalence of mutation signatures that are associated with defects in different DNA repair pathways 43 . We used a cohort of 960 breast cancer tumours that had been analysed for mutation signatures 44 . We found that only signature 3, indicative of HDR deficiency, was differentially prevalent between TRIP13 high -and TRIP13 low -expressing tumours (Fig. 6b ). HDR was increased in tumours expressing high levels of TRIP13, implying that HDRdeficient tumours upregulate TRIP13 expression.
We then investigated whether TRIP13 expression correlates with survival among patients with BRCA1-deficient breast cancer in TCGA. Although these patients were not treated with olaparib, BRCA1-deficient cancers are mainly triple negative cancers and are treated with chemotherapy and radiation therapy to which HDRdeficient cells are also sensitive. We found that patients with high levels of TRIP13 expression had significantly worse overall survival than those with low levels of TRIP13 expression ( Fig. 6c ), suggesting that cancers that express high levels of TRIP13 are more resistant to treatment, potentially through restoration of HDR.
TRIP13 overexpression promotes HDR and PARPi resistance in BRCA1-deficient breast cancer cells. We proceeded to directly assay the effect of TRIP13 in BRCA1-deficient breast cancer-derived cell lines. We assessed TRIP13 protein levels in a panel of normal and cancer cell lines and observed wide variation (Extended Data Fig. 6c ). We focused on the SUM149PT cell line because it is a widely used BRCA1-deficient model with a high level of TRIP13 expression. Despite their BRCA1 deficiency, SUM149PT cells were partially HDR-proficient, as monitored by RAD51 focus formation and olaparib resistance ( Fig. 6d-f ). We therefore investigated whether TRIP13 promotes HDR in these cells. Indeed, knockdown of TRIP13 significantly impaired both RAD51 focus formation and olaparib resistance ( Fig. 6d-f , Extended Data Fig. 6d ). Interestingly, in contrast to other BRCA1-deficient contexts 7,20 , knockdown of REV7 or 53BP1 did not cause an appreciable increase in RAD51 focus formation in SUM149PT cells ( Fig. 6e ,f, Extended Data Fig. 6e ). This is probably because the 53BP1-REV7-Shieldin axis in these cells is already inactivated by their high level of TRIP13 expression.
Having shown that TRIP13 expression is necessary for PARPi resistance in a cancer cell line ( Fig. 6 ), we wanted to determine whether TRIP13 overexpression is sufficient for induction of resistance in an engineered BRCA1-mutant RPE-1 cell line 45 . We confirmed that knockdown of REV7 partially restored olaparib resistance in this cell line (Extended Data Fig. 6f ). Overexpression of TRIP13 in this setting resulted in a notable induction of olaparib resistance (Extended Data Fig. 6g ), demonstrating that TRIP13 overexpression is a bona fide mechanism of PARPi resistance.
Discussion
Post-translational regulation of proteins is ubiquitous in the DNA damage response 46, 47 . In contrast to conventional covalent modifications of residues, we describe a post-translational regulatory mechanism in which REV7 is regulated by stable modifications to its tertiary structure. Furthermore, we pinpointed the REV7interacting protein TRIP13 as a negative regulator of REV7 by promoting its conformational transition. Given the importance of the Shieldin complex in determining PARPi resistance, its mechanism of regulation is an important open question. Here we reveal an important participant, the conserved AAA+ ATPase TRIP13; however, the stimuli that control the action of TRIP13 and association and dissociation of REV7-Shieldin remain unknown. Moreover, unbound C-REV7 rapidly converts to inactive O-REV7, strongly suggesting that the generation of C-REV7 is an active process that requires other factors, the discovery of which will shed light on the function of REV7.
We have shown that TRIP13 regulates REV7 function in two distinct complexes-Shieldin and Pol-ζ. It is interesting that cells use the same regulatory system for multiple DNA repair pathways. Although the pathways have not previously been known to be linked, they are related in that both DSBs and replication blockage present a decision point for the cell. A DSB can be repaired by quick, albeit error-prone, NHEJ or through high-fidelity HDR. Similarly, a replication fork can proceed past a lesion using mutagenic TLS or more energy-and time-intensive error-free pathways of fork regression or template-switching bypass 48 . TRIP13 is therefore positioned to play a critical role in the choice between mutagenic and highfidelity pathways.
Furthermore, we show that TRIP13 activity is clinically relevant. Previous studies have noted that TRIP13 is overexpressed in various cancers and is a negative prognostic marker [49] [50] [51] . Interestingly, biallelic loss-of-function TRIP13 mutations were recently reported in Wilms tumours, and these cells expectedly have a SAC defect 52 . Whether they also have lower HDR capacity and chemotherapeutic resistance is an important question for future research. Although we have learned a great deal about PARPi resistance mechanisms through the discovery of 53BP1, RIF1, Shieldin and CST-DNA polymerase alpha, there has been little progress in identifying a druggable target. As an enzymatic negative regulator of the Shieldin complex, TRIP13 is an ideal drug target. It is of great clinical importance to further explore the utility of TRIP13 inhibition to potentiate the clinical effectiveness of PARPi.
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Methods
Cell culture and transfections. Human HeLa, HEK293T and U2OS cells were grown in DMEM (Invitrogen), SUM149PT and RPE-1 cells were cultured in DMEM-F12 (Invitrogen), and HCC1937 cells were maintained in RPMI (Invitrogen) medium; all medium was supplemented with 10% fetal calf serum (FCS) and penicillin-streptomycin (1%). Breast and ovarian cell lines used in Fig. 6 were cultured according to recommendations in the literature 53, 54 . DNA transfections and siRNA knockdowns were performed using Lipofectamine LTX (Invitrogen) and RNAiMax (Invitrogen), respectively, according to the manufacturer's protocols. The RNAi target sequences used in this study were as follows: CAGGGTATCGACGATTACAAA (siControl), AAGATGCAGCTTTACGTGGAA (siREV7), TTGGGACAGCTTGGTATACGA (siTRIP13-1), AAGCAAATCACTGGGTTCTAC (siTRIP13-6), TGTCTGATCACTGAACGGAAA (siMAD2) and TTGAAGAATGCAGGTTTAATA (siBRCA2).
Antibodies and chemicals.
The antibodies used in this study were as follows: Santa Cruz, sc-135977 (anti-REV7, IF, 1:100 dilution); Abcam, ab180579 (anti-REV7, IB, 1:1,000 dilution); Abcam, ab128171 (anti-TRIP13, 1:1,000 dilution); Cell Signaling, 2144 (anti-tubulin, 1:5,000 dilution); Novus, NB100544 (anti-pRPA32 S33, IF, 1:5,000 dilution); Santa Cruz, sc-8349 (anti-RAD51, IF, 1:100 dilution); Cell Signaling, 4937 (anti-53BP1, IF, 1:1,000 dilution); Bethyl, A300-569A (anti-RIF1, IF, 1:1,000 dilution); Santa Cruz, sc-138 (anti-GST, 1:1,000 dilution). MMC was purchased from Sigma and olaparib was purchased from Selleckchem.
Mass spectrometry analysis of tandem-affinity-purified protein complexes.
FLAG-HA tagged Rev7 complexes were purified by tandem affinity purification (TAP), and complexes from three independent biological replicates were analysed using mass spectrometry as described previously with minor modifications 55 . First cysteine residues were reduced using 10 mM dithiothreitol (DTT) for 30 min at 56 °C in the presence of 0.1% RapiGest SF (Waters) and were subsequently alkylated with 20 mM iodoacetamide for 20 min at room temperature in the dark. Proteins were digested overnight at 37 °C using 5 μg of trypsin after adjusting the pH to 8.0 with Tris. Digests were acidified by adding trifluoroacetic acid to a final concentration of 1% and incubated at 37 °C for 30 min. Cleaved RapiGest products were pelleted by centrifugation (20,000g) at room temperature for 10 min. Supernatants were desalted by batch-mode reverse phase (Poros 10R2, Applied Biosystems) solid-phase extraction and concentrated in a vacuum concentrator. Peptides were solubilized in 0.1% formic acid containing 25% acetonitrile and further purified by batch-mode strong cation exchange (Poros 10HS, Applied Biosystems). Peptides were finally eluted with 0.1% formic acid containing 25% acetonitrile and 300 mM KCl and were then concentrated by vacuum centrifugation. Purified peptides were loaded onto a precolumn (4 cm × 150 µm POROS 10R2, Applied Biosystems) and eluted using an high-performance liquid chromatography gradient (NanoAcquity UPLC system, Waters; 10%-40% B in 60 min; A, 0.2 M acetic acid in water; B, 0.2 M acetic acid in acetonitrile). Peptides were resolved on a self-packed analytical column (50 cm × 150 µm Monitor C18, Column Engineering) and were analysed using a mass spectrometer (Q Exactive HF mass spectrometer, Thermo) equipped with a Digital PicoView electrospray source platform (New Objective). The spectrometer was operated in data dependent mode whereby the top ten most abundant ions in each MS scan were analysed by HCD fragmentation (30% normalized collision energy) and MS2 scans. Dynamic exclusion was enabled with a repeat count of 1 and exclusion duration of 30 s. Peak lists were extracted using multiplierz scripts [56] [57] [58] and were converted into a Mascot generic file format (.MGF). Spectra were searched using Mascot (v.2.6) against three appended databases consisting of: (1) human protein sequences (downloaded from RefSeq on 07/11/2011); (2) common laboratory contaminants; and (3) a decoy database generated by reversing the sequences from these two databases. Precursor tolerance was set to 10 p.p.m. and product ion tolerance was set to 0.02 Da. Search parameters included trypsin specificity with up to two missed cleavages, fixed carbamidomethylation (C, +57 Da) and variable oxidation (M, +16 Da). Spectra matching to peptides from the reverse database were used to calculate a global false discovery rate and were discarded. Data were further processed to remove peptide spectral matches to the forward database with a false discovery rate of greater than 1.0%. Peptides shared by two or more genes were excluded from consideration when constructing the final protein list. Protein abundance was estimated on the basis of the average MS signal response for the three most intense gene-unique tryptic peptides 59 . We generated the final list of binding partners as follows. Proteins that were identified in any of a set of 108 negative control tandem affinity purification (TAP) experiments 60 or in any of the three control TAP experiments performed alongside the three REV7 TAP experiments were excluded from consideration. Finally, we only considered binding partners that were identified and quantified in at least two out of the three replicate REV7 purifications. IP analysis. Cells were first lysed in 150 mM NaCl NP-40 buffer for 30 min with rocking at 4 °C. Clarified lysates were then incubated with the appropriate antibody-bead conjugate for 2 h to overnight (16 h) at 4 °C. Beads were washed at least three times with 150 mM NaCl NP-40 buffer and immunoprecipitates were eluted by either competition with 0.5 mg ml −1 Flag peptide or boiling.
Drug sensitivity and functional cell-based reporter assays. To assess clonogenic survival, cells were transfected twice with the indicated siRNAs over 48 h, collected and seeded at a low density (1,000-3,000 cells per well) in 6-well plates in triplicates. Drugs at the indicated doses were added after 12 h and cells were allowed to grow for 14 d. Colony formation was scored by fixing and staining with 0.5% (w/v) crystal violet in methanol. For short-term survival assays, siRNA-transfected cells were plated in 96-well plates at 1,000 cells per well and were treated with drugs at the indicated concentration after 12 h. Then, 3 d later, cellular viability was assayed using CellTiterGlo (Promega). Survival at each drug concentration for both clonogenic and CellTiterGlo assays was calculated as a percentage relative to the corresponding untreated control. Direct repeat homologous recombination efficiency was measured using the U2OS DR-GFP reporter cell line as previously described 37 .
Generation of knockout cell lines using CRISPR-Cas9. All of the guide RNA sequences were cloned into the pSpCas9(BB)-2A-GFP vector, a gift from F. Zhang (Addgene plasmid, 48138). Cells were transfected with Cas9-gRNA plasmids and, 48 h later, GFP + cells were selected and seeded as single cells using a BD FACSAria II cell sorter. Single cells were grown for approximately 3 weeks and colonies were screened for knockouts by western blotting. The gRNA target sequences used in this study were as follows: GAGGTCTTGTCGTGTGAGCG (REV7), CGAGTCGCCAACGGTCCACG (TRIP13-1), CACGTGGACCGTTGGCGACT (TRIP13-2).
Cellular fractionation and immunoblot analysis. Cells were lysed with NP-40 buffer (1% NP-40, 300 mM NaCl, 0.1 mM EDTA, 50 mM Tris pH 7.5) supplemented with protease inhibitor cocktail (Roche). Cell lysate was resolved by gel electrophoresis using NuPAGE Novex gels (Invitrogen), and proteins were transferred onto nitrocellulose membranes, sequentially incubated with primary and secondary antibodies, and detected by chemiluminescence. For chromatin fractionation, the cell pellets obtained described above were resuspended in MNase buffer (1% NP-40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris pH 7.5, 0.5% NP-40, 10% glycerol, 2 mM CaCl 2 ) with MNase (Roche) at a final concentration of 3 U μl −1 and incubated at 37 °C with shaking for 15 min. An equal volume of 2× HA-IP buffer (1% NP-40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris pH 7.5, 0.05% NP-40, 10% glycerol) was added and the tubes were incubated on ice for 15 min. The supernatant was collected after centrifugation at maximum speed, and chromatin-bound proteins were precipitated using 50% trichloroacetic acid and resuspended in NP-40 buffer. The fractions were probed with different antibodies using gel electrophoresis.
Protein purification. cDNA sequences encoding REV7 R124A and REV7 R124A Δseatbelt were cloned into the pET28a vector with an N-terminal His-tag fusion. TRIP13 and SHLD3 cDNA were cloned into pGEX-GP6 with an N-terminal GST-tag fusion, TRIP13 was cloned with a TEV-cleavable His tag C-terminally located to GST. Proteins were expressed in BL21 (DE3) or BL21 (DE3) Rosetta E. coli strains (EMD Millipore). Expression was induced by addition of 1 mM isopropyl-β-dthiogalactoside (IPTG) at 16 °C to logarithmically growing cultures. Cells were lysed in lysis buffer (for His-purification, 50 mM Tris-HCl pH 7.5, 350 mM NaCl, 20 mM imidazole, 0.5 mM EDTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10% glycerol; for GST purification, 1× PBS + 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 1 mM PMSF) by successive freeze-thaw cycles followed by sonication. Lysates were incubated with Ni-NTA agarose (Qiagen) or glutathione agarose (Life Technologies) for 1-4 h and then beads were then washed with wash buffer (for His-purification, 50 mM Tris-HCl pH 7.5, 1 M NaCl, 20 mM imidazole, 0.5 mM TCEP, 10% glycerol; for GST-purification, 1× PBS + 350 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine, TCEP) and eluted with 300 mM imidazole for Hispurification or 10 mM reduced glutathione for GST-purification. The GST tag was cleaved from TRIP13 using PreScission protease (GE Healthcare) and His-tagged TRIP13 was processed for another round of purification using the above protocol. The His-tag was subsequently cleaved by TEV protease (Sigma Aldrich).
Analytical and preparative protein chromatography. Size exclusion chromatography and AEC were performed using an AKTApurifier system. SEC was performed using the Superdex Increase 10/300 column (GE Healthcare) and AEC was performed using the HiTrap Q HP 1 ml column (GE Healthcare). For purified REV7, the eluate was concentrated to 500 μl and injected into the SEC column, which was equilibrated with buffer A (20 mM Tris-HCl, pH 7.5, 20 mM NaCl, 0.5 mM TCEP, 10% glycerol), and 500 μl fractions were eluted and analysed using SDS-PAGE and Coomassie Blue staining. Fractions containing monomeric REV7 were pooled and directly injected into the AEC column; 500 μl fractions were eluted as a gradient of 0-50% Buffer B (20 mM Tris-HCl pH 7.5, 1 M NaCl, 0.5 mM TCEP, 10% glycerol). Fractions were again analysed using SDS-PAGE and either Coomassie staining or western blot. The REV3 SBM used for C-REV7 stabilization experiments was N-terminally biotinylated RTANILKPLMSPPSREEIMA (Selleck). For SEC of cell lysates, 300 μl of clarified cell lysate was injected into the SEC column, which was equilibrated with 50 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA and 10% glycerol, and 500 μl fractions were collected. To enhance signal, proteins in each fraction were precipitated using trichloroacetic acid and the protein was dissolved in 20 μl SDS loading buffer and loaded for SDS-PAGE analysis. Endogenous REV7 was visualized by western blot. 15 N-labelled HSQC NMR. The 15 N-HSQC spectra of 15 N-labelled REV7 proteins were acquired in 20 mM HEPES, 100 mM NaCl and 10 mM DTT, pH 7.4 with 10% D 2 O at 25 °C using a 600 MHz Bruker Avance II spectrometer with a Prodigy cryoprobe. The data were collected with 48 scans, 512 complex points in the direct 1 H dimension and 64 complex points in the 15 N indirect dimension.
GST pull-downs. GST-tagged proteins were expressed in the Rosetta (DE3) E. coli strain by induction with 1 mM IPTG overnight at 16 °C. Lysates were incubated with glutathione agarose beads (Thermo Scientific) for 4 h. Beads were then washed sequentially with PBS with 300 mM NaCl and PBS with 500 mM NaCl. The beads were then rinsed with 150 mM NaCl NP-40 buffer and purified REV7 was added after adjusting salt concentrations to 150 mM NaCl as required. The beads-REV7 mixture was then incubated overnight with rocking at 4 °C. The beads were washed at least three times with 150 mM NaCl NP-40 buffer and GST-protein complexes were eluted with 10 mM reduced glutathione and analysed by western blotting.
ATPase assays. TRIP13 ATPase activity was measured using the ADP-Glo Kit (Promega). Purified TRIP13 was diluted to the appropriate concentration in ATPase dilution buffer such that the final buffer makeup was 25 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM MgCl 2 , 1 mM DTT and 5% glycerol 33 with 1 mM Ultrapure ATP (Promega). We set up 5 μl reactions in triplicate in opaque 384-well plates and allowed the reactions to proceed for various times. The reaction was stopped by addition of 5 μl ADP-Glo reagent and 10 μl of kinase detection reagent and ATP consumption was measured on the basis of the luminescence generated from each well.
In vitro TRIP13 dissociation assays. Glutathione-agarose bound REV7-SHLD3 complexes were pre-assembled by incubating the beads with GST-SHLD3 followed by incubation with His-tagged REV7 and washing to remove any unbound protein.
The SHLD3-REV7 bound beads were then incubated with purified TRIP13 in assay buffer (25 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 5% glycerol) with or without addition of 2 mM ATP or AMP-PNP. The tubes were shaken at 37 °C. At various timepoints, aliquots were collected from the reaction and the soluble unbound fraction was separated from the complex-bound beads using spin columns (EMD Millipore). The collected samples were then analysed using SDS-PAGE and western blotting for REV7.
SMART DNA fibre assays. The SMART assay procedure was performed largely as described previously 39 . Cells were grown in the presence of BrdU for 24 h to label genomic DNA. The cells were then exposed to X-ray irradiation to induce DSB formation. Cells were collected 6 h after irradiation. To avoid DNA breakage, cells were encased in low-melting-point agarose plugs before lysis overnight in 0.5 M EDTA and 1% Sarkosyl with proteinase K (Fisher) at 50 °C. Genomic DNA containing plugs were then washed with TE buffer. The plugs were then placed in spreading buffer (0.5 M MES, pH 5.5) and melted at 68 °C; agarose was digested by overnight incubation at 42 °C with β-agarase (NEB). The next day, the genomic DNA solution was spread onto silanized coverslips using the Fiber Comb system (Genomic Vision). Combed coverslips were then dried in an oven at 65 °C for 2 h before blocking with 3% BSA for 30 min at 37 °C. Coverslips were then incubated with primary anti-BrdU antibodies (GE Healthcare) in 3% BSA overnight at 4 °C. The next day, coverslips were washed with PBST and incubated with secondary Alexa-594-labelled goat anti-mouse antibodies (Life Technologies) for 30 min at 37 °C. The coverslips were washed again and mounted on slides with Vectashield mounting medium (Vector laboratories). Images were captured using a Zeiss AX10 fluorescence microscope and Zen software, and fibre lengths were measured using ImageJ. At least 100 fibres were scored per condition.
Immunofluorescence assays. Cells were plated on glass cover slips in 12-well plates. The next day, the cells were either left untreated or were irradiated at the indicated doses and collected at the indicated time points by pre-extracting with 0.5% Triton X-100 for 5 min, followed by fixing with 4% paraformaldehyde for 10 min at 4 °C. For REV7 foci, an additional 10 min methanol-extraction step was performed. The wells were washed three times with PBS, blocking was performed with 3% BSA in PBS for 1 h at room temperature, followed by incubation with primary and secondary antibodies for 1 h at room temperature or overnight at 4 °C. The coverslips were then mounted onto glass slides with DAPI-containing medium (Vector Laboratories). Foci were scored and images were captured using a Zeiss AX10 fluorescence microscope and Zen software. At least 100 cells were counted for each sample.
Chromosomal breakage analysis. HEK293T cells were transfected twice with the indicated siRNAs or once with the indicated expression constructs and incubated for 48 h with or without the indicated doses of MMC. The cells were treated with 100 ng ml −1 of colcemid for 2 h and then treated with a hypotonic solution (0.075 M KCl) for 20 min and fixed with 3:1 methanol:acetic acid. The slides were stained with Wright's stain and 50 metaphase spreads were scored for aberrations. The relative number of chromosomal breaks and radials was calculated relative to control cells or empty vector control as indicated in the figure legends. supF mutagenesis assay. supF assays were performed largely as described previously 61 . In brief, HEK293T cells treated with the indicated siRNAs were transfected with either undamaged or UVC-treated (1,000 J m −2 using a 2400 UV Stratalinker) pSP189 plasmid using Lipofectamine LTX reagent. Repair was allowed to proceed for 48 h, after which plasmid DNA was retrieved from the cells using the Wizard Plus SV miniprep kit (Promega). Unreplicated plasmid DNA was eliminated by digestion with DpnI and repaired plasmid was precipitated by ethanol and electroporated into the MBM7070 reporter bacterial strain with an amber mutation in the β-galactosidase gene. Transformed bacteria were plated onto medium containing 100 μg ml −1 ampicillin, 1 mM IPTG and 100 μg ml −1 X-gal. Mutant colonies were detected as white colonies, and mutation frequency was scored as the ratio of white to total number of colonies.
TCGA data acquisition and analysis. TCGA mutation and expression data were downloaded from cBioportal 62, 63 . The METABRIC dataset was used for survival analysis and TRIP13 expression in BRCA1-mutant breast cancers 64 . For the breast cancer analysis, tumours were stratified by median TRIP13 expression and ovarian cancers were stratified by the presence or absence of TRIP13 amplification. Mutation signature analysis was performed for breast cancer using the TCGA 2012 dataset, with signature data acquired from mSignatureDB 44, 65 . For this analysis, tumours were stratified by median TRIP13 expression.
Statistics and reproducibility.
Data are mean ± s.e.m. for n = 3 or more independent experiments. For clonogenic survival assays, significance was calculated using two-way ANOVA. For focus formation and DR-GFP assays, significance was calculated using two-tailed Student's t-tests. For the SMART assay, significance was determined using Mann-Whitney U-tests. For survival analysis of TCGA data, significance was determined using Gehan-Breslow-Wilcoxon tests. For mutation signature and TRIP13 expression analysis from TCGA data, significance was determined using Mann-Whitney U-tests. All statistical analysis was performed using GraphPad Prism 6 (GraphPad Software). For the supF mutagenesis assay in Fig. 5e, 14 -d clonogenic assay in Fig. 6d and RAD51 focus formation assay in Extended Data Fig. 4h , data are from two independent experiments. Fig. 1 | organization and physical interaction of TRIP13 with Shieldin, and lack of contribution of MAD2 to HDR repair. a, Schematic of TRIP13 functional domains. b, Western blot of FLAG IP from HEK293T cells transfected with FLAG-empty vector or FLAG-REV7, SHLD1, SHLD2 or SHLD3. c, Repeats of pulldowns in (b) with or without DNA damage. d, Western blot FLAG-REV7 IPs showing the interaction with endogenous TRIP13 following treatment with the indicated DNA damaging agents. e, Western blot of REV7 and TRIP13 from U2OS wild type, REV7 -/-, TRIP13 -/-, pBabe empty vector and pBabe-TRIP13. f. Western blot showing the expression of Wild-type and E252Q ATPase-dead forms of TRIP13. g, 14-day clonogenic survival assay of U2OS cells expressing Empty vector, wild-type TRIP13 or TRIP13-E253Q treated with indicated doses of olaparib. n=3 biologically independent experiments, Empty vector vs. TRIP13 wild-type: p = 0.005, Empty vector vs. TRIP13-E253Q: p = 0.81 (2-Way ANOVA). h, 5-day cytotoxicity analysis of U2OS cells transfected with nontargeting, REV7-or MAD2-targeted siRNA and treated with indicated doses of Olaparib. n=3 biologically independent experiments, siCtrl vs siREV7: p < 0.0001, siCtrl vs. siMAD2: p = 0.12 (2-Way ANOVA). i, Western blot showing knockdown of MAD2 and REV7 in U2OS cells used for (h). j, Percentage of GFP-positive cells following infection of U2OS DR-GFP cells with I-SceI adenovirus with knockdown of BRCA1 or MAD2. n=3 biologically independent experiments, siCtrl vs. siBRCA1: p = 0.009, siCtrl vs. siMAD2: p = 0.99. k, 14-day clonogenic survival assay of wild-type, TRIP13 -/or TRIP13 -/-REV7 -/-U2OS cells treated with indicated doses of olaparib. n=3 biologically independent experiments, TRIP13 -/vs. TRIP13 -/-REV7 -/-: p = 0.02 Fig. 4 | Effects of TRIP13 knockout and overexpression in HDR assays. a, Quantification of resected ssDNA in U2OS cells expressing pBabe-empty vector or pBabe-TRIP13 measured by SMART assay. Lines indicate mean and SEM, n = approximately 100 fibers per genotype, p<0.0001 (Mann-Whitney test, two-tailed). b, Representative images for (a), with BrdU in exposed ssDNA tracts labeled red. (Scale bar: 1 μm) c, Proportion of U2OS cells expressing pBabe-empty vector or pBabe-TRIP13 with greater than 10 p-RPA32(S33) foci 6 hours following IR treatment. n = 3 biologically independent experiments, p = 0.002 (Student's t-test, two-tailed). d, Western blot showing TRIP13 knockout in HeLa cells. e, Proportion of HeLa cells with greater than 10 p-RPA32(S33) foci 6 hours following IR treatment. f. Western blot showing RPA32 phosphorylation (S33) and H2AX phosphorylation, with or without irradiation in wild-type or TRIP13 -/-U2OS cells, expressing Empty vector or TRIP13-E253Q. g, Proportion of U2OS cells expressing Empty vector or TRIP13 with greater than 10 RAD51 foci 6 hours following IR treatment. n = 3 biologically independent experiments, p = 0.01 (Student's t-test, two-tailed). h, Proportion of HeLa cells with more than 10 RAD51 foci 6 hours following IR treatment. n=2 biologically independent experiments. i, Western blot showing TRIP13 knockdown for DR-GFP experiment in 4g. j, Percentage of GFP-positive cells following infection of U2OS DR-GFP cells expressing FLAG empty vector or FLAG-TRIP13 with I-SceI adenovirus. n = 3 biologically independent experiments, p = 0.05 (Student's t-test, two-tailed). All error bars indicate SEM. All immunoblots are representative of at least 2 independent experiments. Fig. 5 | Effects of TRIP13 deficiency in TLS assays. a, Schematic of the SupF assay. Plasmids are damaged by exposure to a high UV dose. Damaged plasmids are transfected into HEK293T cells and allowed to replicate, accumulating mutations. Plasmids are isolated from cells and transformed into a reporter E. coli strain. Functional SupF expression allows for readthrough of a premature stop codon in the LacZ gene. Any mutations in SupF give LacZ-colonies. b, 14-day clonogenic survival assay of U2OS wild-type, TRIP13 -/or REV7 -/cell lines treated with indicated mitomycin C (MMC) doses. n=3 biologically independent experiments, Wild-type vs. TRIP13 -/-#3: p = 0.19, Wild-type vs. TRIP13 -/-#7: p = 0.15, Wild-type vs. REV7 -/-: p < 0.0001 (2-Way ANOVA) c, 14-day clonogenic survival assay of U2OS wild-type, TRIP13 -/or REV7 -/cell lines treated with indicated UV doses. n=3 biologically independent experiments, Wild-type vs. TRIP13 -/-#3: p = 0.23, Wild-type vs. TRIP13 -/-#7: p = 0.21, Wild-type vs. REV7 -/-: p < 0.0001 (2-Way ANOVA). d, (Top) Table summarizing effect 
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